Optimizing biomarkers and endpoints in oral cancer chemoprevention trials

Cancer Prevention Research

Volumn 6, Issue 5, 2013, Pages 375-378

  William, William N ^a   Papadimitrakopoulou, Vassiliki A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOWMAN BIRK INHIBITOR; CHYMOTRYPSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEINASE; TRYPSIN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; CLINICAL PRACTICE; COLON CANCER; FOLLOW UP; GENOTYPE; HUMAN; LEUKOPLAKIA; MOUTH CANCER; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE CANCER; REVIEW; SMOKING; SOYBEAN; TUMOR CELL; TUMOR INVASION;

EID: 84877255814     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0114     Document Type: Review

References (30)

1. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, et al. Progress inchemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer - a plan to move forward. Clin Cancer Res 2006; 12:3661-97. (Pubitemid 44000248)
2. William WN Jr. Oral premalignant lesions: any progress with systemic therapies? Curr Opin Oncol 2012; 24:205-10.
3. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, et al. Bowman Birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res 2013; 6:410-18.
4. Talalay P. The importance of using scientific principles in the development of medicinal agents from plants. Acad Med 2001; 76:238-47. (Pubitemid 32199656)
5. Moiseeva EP, Manson MM. Dietary chemopreventive phytochemicals: too little or too much? Cancer Prev Res 2009; 2:611-6.
6. Scott EN, Gescher AJ, Steward WP, Brown K. Development of dietary phytochemical chemopreventive agents: biomarkers and choice of dose for early clinical trials. Cancer Prev Res 2009; 2:525-30.
7. Kennedy AR. Chemopreventive agents: protease inhibitors. Pharmacol Ther 1998; 78:167-209. (Pubitemid 28255148)
8. Manzone H, Billings PC, Cummings WN, Feldman R, Clark LC, Odell CS, et al. Levels of proteolytic activities as intermediate marker end-points in oral carcinogenesis. Cancer Epidemiol Biomarkers Prev 1995; 4:521-7.
9. Kennedy AR, Billings PC, Maki PA, Newberne P. Effects of various preparations of dietary protease inhibitors on oral carcinogenesis in hamsters induced by DMBA. Nutr Cancer 1993; 19:191-200. (Pubitemid 23131436)
10. Messadi DV, Billings P, Shklar G, Kennedy AR. Inhibition of oral carcinogenesis by a protease inhibitor. J Natl Cancer Inst 1986; 76:447-52. (Pubitemid 16119780)
11. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL Jr. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 2000; 9:43-7. (Pubitemid 30062908)
12. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000; 6:4684-91. (Pubitemid 32110405)
13. Wan XS, Meyskens FL Jr, Armstrong WB, Taylor TH, Kennedy AR. Relationship between protease activity and neu oncogene expression in patients with oral leukoplakia treated with the Bowman Birk inhibitor. Cancer Epidemiol Biomarkers Prev 1999; 8:601-8. (Pubitemid 29337320)
14. Mehta FS, Shroff BC, Gupta PC, Daftary DK. Oral leukoplakiainrelation to tobacco habits. A ten-year follow-up study of Bombay policemen. Oral Surg Oral Med Oral Pathol 1972; 34:426-33.
15. Silverman S, Bhargava K, Smith LW, Malaowalla AM. Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers of Gujarat, India. Cancer 1976; 38:1790-5.
16. Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980; 8:283-333.
17. Pindborg JJ, Roed-Peterson B, Renstrup G. Role ofsmoking in floor of the mouth leukoplakias. J Oral Pathol 1972; 1:22-9.
18. Banoczy J. Follow-up studies in oral leukoplakia. J Maxillofac Surg 1977; 5:69-75.
19. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol 2003; 39:770-80. (Pubitemid 38373461)
20. Papadimitrakopoulou VA, Lee JJ, William WN Jr, Martin JW, Thomas M, Kim ES, et al. Randomized trialof13-cis retinoicacid comparedwith retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 2009; 27:599-604.
21. Burkhardt A, Maerker R. Dysplasieklassifikation oraler leukoplakien und präkanzerosen. Bedeutung für prognose und therapie. Dtsch Z Mund-Kiefer-Gesichts-Chir 1978; 2:199-205.
22. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, et al. Predicting cancer development in oral leukoplakia: ten years of trans-lational research. Clin Cancer Res 2000; 6:1702-10. (Pubitemid 30305062)
23. Cruz IB, Snijders PJ, Meijer CJ, Braakhuis BJ, Snow GB, Walboomers JM, et al. p53 expression above the basal cell layerinoral mucosaisan early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 1998; 184:360-8.
24. Pindborg JJ, Reibel J, Holmstrup P. Subjectivity in evaluating oral epithelial dysplasia, carcinoma in situ and initial carcinoma. J Oral Pathol 1985; 14:698-708.
25. Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 80:188-91.
26. Karabulut A, Reibel J, Therkildsen MH, Praetorius F, Nielsen HW, Dabelsteen E. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med 1995; 24:198-200.
27. Mao L, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998; 90:1545-51. (Pubitemid 28535719)
28. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40. (Pubitemid 19105891)
29. William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009; 8: 213-25.
30. Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, et al. Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res 2011; 4:347-53.